Analysis WuXi Biologics (WXIBF)
5/30/2024
Analysis of WuXi Biologics (WXIBF)
WuXi Biologics (WXIBF) has been showing some interesting price movements recently. The stock closed at 2.46 on the most recent trading day, with an RSI indicator of 71.42, indicating it may be overbought. The MACD indicator is positive, suggesting a bullish trend, and the Moving Average (MA) indicator is also above the current price, indicating a potential uptrend.Looking at historical data, we can see that the stock has been fluctuating between 1.46 and 2.46 in the past few days. The RSI indicator has been hovering around 40, indicating a neutral position, while the MACD indicator has been fluctuating around 0, suggesting a lack of clear trend direction.
Overall, WuXi Biologics seems to be in a consolidation phase, with some bullish signals in the short term. However, investors should keep an eye on the RSI and MACD indicators for potential trend reversals.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, peaking at $234,386,000,000 in 2018.
4. Total liabilities have also been on the rise, with the highest value in 2018 at $255,355,000,000.
5. Shareholders' equity has generally increased, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to support its operations.
7. There has been a consistent increase in shareholders' equity, indicating a positive trend in the company's financial health.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided yet. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.Financials:
- Cash flow: Operating cash flow TTM is $110,563,000,320 and levered free cash flow TTM is $84,726,874,112.
- Balance sheet: Total cash MRQ is $67,150,000,128, total debt MRQ is $104,590,000,128, current ratio MRQ is 1.037, book value per share MRQ is $4.837, total cash per share MRQ is $4.379, total debt to equity MRQ is 140.968.
- Profit margin: 26.306%.
- Fiscal year ends: September 30, 2023.
- Income statement: EBITDA is $131,393,000,000, revenue TTM is $381,623,009,280, diluted EPS TTM is $6.43, gross profit TTM is $169,148,000,000, revenue per share TTM is $24.537, net income to common TTM is $100,389,003,264, quarterly revenue growth is -4.3%, quarterly earnings growth YoY is -2.2%.
- Operating margin: 30.743%.
- Most recent quarter: March 31, 2024.
- Return on assets TTM: 22.073999%.
- Return on equity TTM: 147.25%.
Stock statistics:
- Short ratio: 1.53.
- Float shares: 15,308,320,742.
- Shares short: 99,287,450.
- Average 10-day volume: 46,860,048.
- Average 90-day volume: 57,498,254.
- Shares outstanding: 15,334,099,968.
- Percent held by insiders: 5.22%.
- Percent held by institutions: 57.589%.
- Short percent of shares outstanding: 0.65%.
Valuation metrics:
- PEG ratio: 26.319502.
- Forward PE: 26.319502.
- Trailing PE: 29.59409.
- Enterprise value: $2,950,762,332,160.
- Price to book MRQ: 39.3405.
- Price to sales TTM: 7.646095.
- Enterprise to EBITDA: 22.763.
- Enterprise to revenue: 7.732.
- Market capitalization: $2,917,925,650,432.
Stock price summary:
- Beta: 1.264.
- 50-day moving average: $176.2646.
- 200-day moving average: $181.0429.
- 52-week low: $164.08.
- 52-week high: $199.62.
- 52-week change: 6.853%.
Dividends and splits:
- Payout ratio: 14.93%.
- Dividend date: May 16, 2024.
- Last split date: August 31, 2020.
- Ex-dividend date: May 10, 2024.
- Last split factor: 4-for-1 split.
- Forward annual dividend rate: $1.
- 5-year average dividend yield: 0.73%.
- Forward annual dividend yield: 0.5255%.
- Trailing annual dividend rate: $0.97.
- Trailing annual dividend yield: 0.5097%.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the past four years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the net income has also shown a positive trend, growing from $57.4 billion in 2020 to $97 billion in 2023.
3. The company's EBITDA has also been increasing over the years, indicating improved operational efficiency.
4. The basic and diluted earnings per share (EPS) have remained relatively stable over the years, with slight fluctuations.
5. The company has been able to maintain a healthy gross profit margin, despite fluctuations in the cost of goods sold.
6. Operating income and EBIT have shown an increasing trend, reflecting the company's ability to effectively manage its operating expenses.
7. The company has been able to generate consistent income from its core operations, as seen in the net income from continuous operations.
8. Overall, the financial performance of the company seems to be on a positive trajectory, with increasing revenues and profitability over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its peak in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with some fluctuations in different areas that may require further analysis.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and years, with an increase compared to the previous year's EPS in most cases. This indicates potential growth and improvement in the company's financial performance according to analysts' projections.
Revenue estimate
Based on analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates indicate a generally positive outlook for the company, with expected growth in both quarterly and annual sales over the coming quarters and years.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. The company is projected to experience steady growth in the upcoming quarters and years, indicating a positive outlook according to analyst consensus.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.MACD of WXIBF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
